There is no cure for any form of muscular dystrophy. Despite decades of research and several promising therapies reaching the market, no treatment has been able to fully stop or reverse the disease. What has changed dramatically is how well muscular dystrophy can be managed: modern care has extended life expectancy, slowed muscle loss, and improved quality of life for many patients.
Why a Cure Has Been So Difficult
Muscular dystrophy isn’t a single disease. It’s a group of more than 30 genetic conditions, each caused by different mutations that disrupt proteins muscles need to function. Duchenne muscular dystrophy (DMD), the most common and severe form, results from mutations in the gene responsible for producing dystrophin, a protein that acts like a shock absorber for muscle fibers. Without it, muscles break down with every contraction and are gradually replaced by scar tissue and fat.
The challenge is that muscle tissue is spread throughout the entire body, making it difficult for any therapy to reach enough cells to restore function. The dystrophin gene is also one of the largest in the human genome, too big to fit inside the viral delivery systems researchers typically use to transport corrective genes into cells. These biological constraints have forced scientists to develop creative workarounds rather than straightforward fixes.
Gene Therapy: The Closest Approach So Far
In June 2023, the FDA approved Elevidys, the first gene therapy for Duchenne muscular dystrophy. Rather than delivering the full dystrophin gene, Elevidys uses a virus to carry a shortened version called micro-dystrophin into muscle cells. This miniaturized protein is roughly one-third the size of normal dystrophin, containing only the most critical structural portions. The idea is that even a partial version of the protein can provide some protection against muscle damage, similar to what’s seen in Becker muscular dystrophy, a milder form of the disease where patients naturally produce a truncated dystrophin.
Elevidys is a one-time infusion, but it is not a cure. It does not restore full dystrophin production, and its long-term effects are still being studied. It’s also limited to certain patients based on age and mutation type, meaning many people with DMD are not eligible.
Exon Skipping Drugs
A separate class of treatments takes a different approach to the dystrophin problem. In DMD, a mutation in one section of the gene prevents the entire protein from being assembled. Exon skipping drugs work by masking the faulty section so the cell can read past it and still produce a shorter but partially functional version of dystrophin.
Four exon skipping drugs have been approved, each targeting a specific mutation:
- Eteplirsen targets exon 51, applicable to about 10% of DMD patients
- Golodirsen and viltolarsen target exon 53, applicable to another 10%
- Casimersen targets exon 45, applicable to roughly 8 to 10%
All four require weekly intravenous infusions. Together, they cover roughly 30% of people with Duchenne. The remaining 70% have mutations that don’t match any currently approved drug. And even for those who are eligible, the amount of dystrophin these drugs help produce is modest. They can slow disease progression, but they don’t halt it.
CRISPR Gene Editing Enters Clinical Trials
Gene editing represents a fundamentally different strategy. Instead of adding a new gene or patching over a mutation temporarily, CRISPR aims to permanently edit the patient’s own DNA. In late 2024, the Chinese biotech company HuidaGene Therapeutics dosed the first patient in a clinical trial using a CRISPR-based approach to skip exon 51 in DMD. The trial plans to treat six patients total at two different doses.
This technology is still in very early stages. A previous attempt by the nonprofit Cure Rare Disease resulted in the first death associated with a CRISPR clinical trial, and it’s unclear whether that program will continue. Gene editing holds enormous theoretical promise because a successful edit would be permanent, but delivering it safely to enough muscle tissue throughout the body remains a major unsolved problem.
Approaches That Haven’t Worked
Several strategies that seemed promising in the lab have failed in human trials. Myostatin inhibitors were designed to block a protein that naturally limits muscle growth, with the hope that removing that brake would help patients build and retain muscle. Three different myostatin-blocking drugs reached randomized trials in DMD patients, and all three were discontinued.
Domagrozumab, a monoclonal antibody, was tested in 121 patients aged 6 to 15. While treated patients showed some increase in muscle volume on MRI, there was no meaningful improvement in functional tests like stair climbing after 49 weeks. Another drug, ACE-031, did increase lean body mass and walking distance, but caused spontaneous bleeding and was dropped for safety reasons. A third, talditercept alfa, was discontinued after predictions showed it would not meet its primary goal of improving motor function at 48 weeks.
How Modern Care Has Changed the Outlook
While no cure exists, the combination of therapies available today has meaningfully extended survival. For people with Duchenne born before 1970, median survival was about 18 years. For those born in the 1990s, it rose to 24 years. Meta-analyses published in 2020 and 2021 estimated median life expectancy at roughly 22 to 24 years. For the most recent birth cohorts, median survival can’t yet be calculated because the majority of individuals are still alive.
Much of this improvement comes from proactive management of the heart and lungs, the two organ systems most threatened by progressive muscle weakness.
On the respiratory side, doctors now monitor breathing muscle strength and introduce assisted ventilation before a crisis occurs. Nighttime ventilation support, assisted coughing techniques, and eventually daytime ventilation have been shown to reduce complications and extend survival significantly. On the cardiac side, early treatment with heart-protective medications starting around age 10, even before symptoms appear, can improve long-term heart function. The heart muscle is affected by the same dystrophin deficiency as skeletal muscle, so early intervention matters.
Corticosteroids remain the backbone of DMD treatment. They slow muscle deterioration, help boys walk longer, and delay the onset of breathing and heart problems. The trade-off is significant side effects with long-term use, including weight gain, bone thinning, and behavioral changes.
Managing Becker and Other Forms
For Becker muscular dystrophy, the milder relative of Duchenne, treatment remains entirely supportive. No disease-modifying therapy has been proven effective. Physical therapy, typically twice-weekly sessions of 30 to 45 minutes, focuses on stretching tight muscles and maintaining mobility. Aerobic exercise is encouraged, but intense contractions and high-impact movements are limited for weaker muscle groups to avoid accelerating damage.
As the disease progresses, occupational therapy addresses daily tasks like dressing and bathing, with adaptations ranging from grab bars and raised toilet seats to powered wheelchairs with custom seating. Speech therapy may be needed if swallowing becomes difficult. Regular monitoring for heart involvement, respiratory decline, pain, and cognitive changes is part of ongoing care.
For many other forms of muscular dystrophy beyond Duchenne and Becker, no approved treatments exist at all. As a 2025 report from the National Institute of Neurological Disorders and Stroke stated plainly: “Many types of MD still lack any treatment.”
What “No Cure” Actually Means Today
The gap between “no cure” and “no hope” has widened considerably. A child diagnosed with Duchenne today faces a very different trajectory than one diagnosed 30 years ago. Gene therapy, exon skipping, corticosteroids, cardiac protection, and respiratory support each chip away at the disease from a different angle. None of them eliminates it, but together they can slow progression, preserve function longer, and add years of life.
The honest answer is that muscular dystrophy cannot yet be cured, and the timeline for a true cure is uncertain. But the range of tools available to fight it is broader than it has ever been, and several of the most ambitious approaches, particularly gene editing, are only now entering human testing.